103 related articles for article (PubMed ID: 18413772)
1. Interleukin 21 enhances antibody-mediated tumor rejection.
Smyth MJ; Teng MW; Sharkey J; Westwood JA; Haynes NM; Yagita H; Takeda K; Sivakumar PV; Kershaw MH
Cancer Res; 2008 Apr; 68(8):3019-25. PubMed ID: 18413772
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.
Curti BD
Expert Rev Anticancer Ther; 2006 Jun; 6(6):905-9. PubMed ID: 16761934
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
4. Preliminary study on mouse interleukin-21 application in tumor gene therapy.
Dou J; Chen G; Wang J; Zhao F; Chen J; Fang X; Tang Q; Chu L
Cell Mol Immunol; 2004 Dec; 1(6):461-6. PubMed ID: 16293216
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-21 signaling: functions in cancer and autoimmunity.
Davis ID; Skak K; Smyth MJ; Kristjansen PE; Miller DM; Sivakumar PV
Clin Cancer Res; 2007 Dec; 13(23):6926-32. PubMed ID: 18056166
[TBL] [Abstract][Full Text] [Related]
6. Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.
Søndergaard H; Coquet JM; Uldrich AP; McLaughlin N; Godfrey DI; Sivakumar PV; Skak K; Smyth MJ
J Immunol; 2009 Dec; 183(11):7326-36. PubMed ID: 19915059
[TBL] [Abstract][Full Text] [Related]
7. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities.
Ho MY; Leu SJ; Sun GH; Tao MH; Tang SJ; Sun KH
J Immunol; 2009 Nov; 183(10):6217-26. PubMed ID: 19841177
[TBL] [Abstract][Full Text] [Related]
8. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma.
Hu P; Hu HD; Chen M; Peng ML; Tang L; Tang KF; Matsui M; Belladonna ML; Yoshimoto T; Zhang DZ; Xiang R; Ren H
Mol Immunol; 2009 May; 46(8-9):1654-62. PubMed ID: 19299021
[TBL] [Abstract][Full Text] [Related]
9. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
10. IL-15-induced CD8+CD122+ T cells increase antibacterial and anti-tumor immune responses: implications for immune function in aged mice.
Motegi A; Kinoshita M; Inatsu A; Habu Y; Saitoh D; Seki S
J Leukoc Biol; 2008 Oct; 84(4):1047-56. PubMed ID: 18653461
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
Hashmi MH; Van Veldhuizen PJ
Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
[TBL] [Abstract][Full Text] [Related]
12. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
13. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
15. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
16. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation.
Hara H; Kobayashi A; Narumi K; Kondoh A; Yoshida K; Nishimoto T; Ohashi M; Higashihara E; Ohnami S; Yoshida T; Aoki K
Cancer Immunol Immunother; 2009 Jul; 58(7):1007-21. PubMed ID: 18998126
[TBL] [Abstract][Full Text] [Related]
18. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
20. Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-gamma.
Vetter M; Hofer MJ; Roth E; Pircher HP; Pagenstecher A
J Neuropathol Exp Neurol; 2009 May; 68(5):525-34. PubMed ID: 19525900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
